IN BRIEF: Poolbeg Pharma celebrates Australian patent "milestone"
Poolbeg Pharma PLC - London-based clinical stage biopharmaceutical firm focused on cancer immunotherapy - Receives formal notification of the grant for its POLB 001 cancer immunotherapy-induced cytokine release syndrome patent application from the IP Australia patent office. Says the patent covers the use of any p38 MAPK inhibitor, including POLB 001, for the prevention of cancer immunotherapy-induced CRS, supported by Poolbeg's proprietary data. "This represents the first national grant within Poolbeg's cancer immunotherapy-induced CRS patent family, marking an important milestone for the company," Poolbeg says. Adds that the grant further strengthens its "robust intellectual property portfolio, enhancing POLB 001's future value and appeal to potential partners." Read More